Trexquant Investment LP Savara Inc Transaction History

Trexquant Investment LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 09, 2019	SELL	$2.37 - $11.7 $39,119 - $193,120	-16,506 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$6.71 - $8.6 $14,272 - $18,292	-2,127 Reduced 11.42%	16,506 $122,000
Q4 2018 Feb 13, 2019	BUY	$6.27 - $10.92 $116,828 - $203,472	18,633 New	18,633 $141,000

138

152M

60.6K

12.3K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $322M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.